Killing of resistant cancer cells with low bak by a combination of an antimesothelin immunotoxin and a TRAIL receptor 2 agonist antibody

Clinical Cancer Research

Volumn 17, Issue 18, 2011, Pages 5926-5934

  Du, Xing ^a   Xiang, Laiman ^a   Mackall, Crystal ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMESOTHELIN(FV)PE38; ANTINEOPLASTIC AGENT; CASPASE 8; IMMUNOTOXIN; LEXATUMUMAB; PROTEIN BAK; PROTEIN BID; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; EMBRYO; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SINGLE DRUG DOSE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL DEATH; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GPI-LINKED PROTEINS; HCT116 CELLS; HELA CELLS; HUMANS; IMMUNOTOXINS; MICE; MICE, NUDE; MITOCHONDRIA; PANCREATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052845094     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1235     Document Type: Article

References (40)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57. (Pubitemid 41486396)
2. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-46. (Pubitemid 41486395)
3. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6:559-65. (Pubitemid 43980544)
4. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345:241-7. (Pubitemid 32695063)
5. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, et al. Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23:6719-29. (Pubitemid 46190267)
6. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 2010;16:1894-903.
7. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42. (Pubitemid 38812466)
8. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008;44:46-53. (Pubitemid 350262830)
9. Li Q, Verschraegen CF, Mendoza J, Hassan R. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. Anticancer Res 2004;24:1327-35. (Pubitemid 38954646)
10. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, et al. Mesothelin expression in human lung cancer. Clin Cancer Res 2007;13:1571-5. (Pubitemid 46450449)
11. Yu L, Feng M, Kim H, Phung Y, Kleiner DE, Gores GJ, et al. Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer 2010;1:141-9.
12. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant antimesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9. (Pubitemid 47502082)
13. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009;15:5274-9.
14. Hassan R, Sharon E, Chen HX, Conlon K, Ling A, Steinberg SM, et al. Phase I clinical trial of antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of advanced pleural mesothelioma. J Clin Oncol 2010;28:e17518.
15. Du X, Youle RJ, FitzGerald DJ, Pastan I. Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1. Mol Cell Biol 2010;30:3444-52.
16. Kreitman RJ, Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 1995;307:29-37.
17. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
18. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57. (Pubitemid 38410779)
19. Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2010;17:666-76
20. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011;25:717-29.
21. Traini R, Ben-Josef G, Pastrana DV, Moskatel E, Sharma AK, Antignani A, et al. ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol. Mol Cancer Ther 2010;9:2007-15.
22. Han J, Goldstein LA, Gastman BR, Rabinovitz A, Wang GQ, Fang B, et al. Differential involvement of Bax and Bak in TRAIL-mediated apoptosis of leukemic T cells. Leukemia 2004;18:1671-80. (Pubitemid 39386346)
23. Theodorakis P, Lomonosova E, Chinnadurai G. Critical requirement of BAX for manifestation of apoptosis induced by multiple stimuli in human epithelial cancer cells. Cancer Res 2002;62:3373-6. (Pubitemid 34651381)
24. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007;13:6187-94. (Pubitemid 350075080)
25. Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 2010;21:376-81.
26. Zeng Y, Wu XX, Fiscella M, Shimada O, Humphreys R, Albert V, et al. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int J Oncol 2006;28:421-30.
27. Zhang L, Zhang X, Barrisford GW, Olumi AF. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett 2007;251:146-57. (Pubitemid 46589773)
28. Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo JA, Jang BS, et al. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 2006;12:4695-701. (Pubitemid 44297823)
29. Zhang Y, Xiang L, Hassan R, Pastan I. Immunotoxin and taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci USA 2007;104:17099-104. (Pubitemid 350210998)
30. Broaddus VC, Dansen TB, Abayasiriwardana KS, Wilson SM, Finch AJ, Swigart LB, et al. Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage. J Biol Chem 2005;280:12486-93.
31. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967-9. (Pubitemid 27087710)
32. Gillissen B, Wendt J, Richter A, Richter A, Müer A, Overkamp T, et al. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J Cell Biol 2010;188:851-62.
33. Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA, et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci USA 2008;105:11317-22.
34. Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, et al. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst 2008;100:649-62.
35. Smith MR, Jin F, Joshi I. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. Clin Cancer Res 2007;13:5528-34s.
36. Hietakangas V, Poukkula M, Heiskanen KM, Karvinen JT, Sistonen L, Eriksson JE. Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. Mol Cell Biol 2003;23:1278-91. (Pubitemid 36177037)
37. Zhang S, Shen HM, Ong CN. Down-regulation of c-FLIP contributes to the sensitization effect of 3,30-diindolylmethane on TRAIL-induced apoptosis in cancer cells. Mol Cancer Ther 2005;4:1972-81. (Pubitemid 43056980)
38. Morizot A, Mérino D, Lalaoui N, Jacquemin G, Granci V, Iessi E, et al. Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ 2011;18:700-11.
39. Boatright KM, Salvesen GS. Mechanisms of caspase activation. Curr Opin Cell Biol 2003;15:725-31. (Pubitemid 37492933)
40. Pop C, Salvesen GS. Human caspases: activation, specificity, and regulation. J Biol Chem 2009;284:21777-81.